A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors
Authors:
- A. Jagiello-GruszfeldAJA. Jagiello-Gruszfeld
- I.N. BondarenkoIBI.N. Bondarenko
- R. PatwardhanRPR. Patwardhan
- C. MessamCMC. Messam
- Y. Mostafa KamelYKY. Mostafa Kamel
- 16 August 2010
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (10) , 2339-2346
Abstract
Objectives:Eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, has been shown to increase platelet counts in adults with chronic immune thrombocytopenia and chronic hepatitis C. This multicenter phase 2 study assessed the efficacy and safety of eltrombopag in patients receiving first-line carboplatin/paclitaxel for the treatment of advanced solid tumors.Research design and methods:Patients (N = 183) were randomized to placebo or eltrombopag 50 mg, 75 mg, or 100 mg given orally following chemotherapy on days 2 through 11 of each 21-day cycle, for at least two cycles. The primary endpoint was the difference in platelet count from day 1 in cycle 2 to the platelet nadir in cycle 2.Clinical trial registry number:NCT00102726.Results:Although the primary endpoint was not met, postnadir platelet counts increased during cycles 1 and 2 in all eltrombopag treatment groups compared with placebo. The most commonly reported adverse events across all study arms (including placebo) were nausea and a...Keywords
This publication has 13 references indexed in Scilit:
- Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet functionExperimental Hematology, 2009
- Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor AgonistStem Cells, 2009
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 2007
- Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis CNew England Journal of Medicine, 2007
- Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonistBlood, 2007
- Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8The Journal of Clinical Pharmacology, 2005
- Hematopoietic Recovery Following Autologous Bone Marrow Transplantation in a Nonhuman Primate: Effect of Variation in Treatment Schedule with PEG‐rHuMGDFStem Cells, 2003
- Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patientsInternational Journal of Clinical Oncology, 2002
- Targeted Approaches for the Treatment of ThrombocytopeniaThe Oncologist, 2001
- Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopeniaCancer Chemotherapy and Pharmacology, 2001